Leading BioSolutions Platform
Arysta LifeScience acquisition transaction summary
Post-acquisition Holding Structure
Promoters
c.28%
ADIA + TPG
c.22%
Equity infusion of
$1.2bn
UPL
c.78%
Public
c.72%
Banks
UPL Corp.
(International business)
Acquisition
Debt: $3bn
100%
Arysta
LifeScience
UPL
o Acquisition made by Mauritius based 100% subsidiary,
UPL Corporation Ltd. (UPLC)
。 Purchase consideration of US$ 4.2 bn
Funding in UPLC via:
о Debt US$ 3 bn
o Equity US$ 1.2 bn
。 After acquisition UPL Ltd.'s stake in UPLC has reduced to
-78%
。 Equity has been subscribed by ADIA and TPG
。 Acquisition transaction closed on January 31, 2019
This entailed unconditional approvals from regulators in
40+ countries
Combined revenues are to the tune of US$ 4.7 bn (as of
March 31, 2019 on trailing twelve months basis)
。 Expected revenue synergies of US$ 300+ mn on run-rate
basis, over 3 years
。 Expected cost synergies of US$ 200+ mn on run-rate
basis, over 2 years
59View entire presentation